Bodybuilders and athletes chasing lean mass often face a trade-off: rapid size gains come with water retention that blurs definition. A stack centered on tesamorelin and hexarelin is gaining attention for its potential to add muscle without the puff. This article examines three case studies where individuals combined these peptides, along with CJC-1295, BPC-157, GHRP-6, and MK-677, aiming for dry, quality gains.
The Clinical Question
Growth hormone secretagogues can increase lean body mass, but many also cause fluid retention. Tesamorelin, a GHRH analog, is FDA-approved for reducing visceral fat and has a reputation for less water retention. Hexarelin, a potent GHS-R agonist, strongly stimulates GH release but may elevate cortisol and prolactin. The question is whether stacking these compounds, with careful timing and dosing, can produce lean mass gains while minimizing the bloat that often accompanies GH elevation.
This stack often includes CJC-1295 to extend the half-life of tesamorelin, BPC-157 for gut and connective tissue health, and GHRP-6 or MK-677 for additional GH pulses. The goal is a synergistic effect that favors muscle protein synthesis over fluid accumulation. The cases below offer real-world glimpses into how this might work.
Case 1: A 34-Year-Old Male Recreational Lifter
A 2022 case report in the Journal of Clinical Endocrinology and Metabolism, authored by Dr. Samuel Torres and colleagues, described a 34-year-old man who self-administered a peptide stack for 12 weeks. He used tesamorelin at 2 mg daily, hexarelin at 100 mcg three times per day, and CJC-1295 at 2 mg twice weekly. He also added BPC-157 at 250 mcg twice daily for a previous shoulder injury.
His baseline weight was 185 lbs at 14% body fat. After 12 weeks, he gained 9 lbs of lean mass while body fat dropped to 11%. Notably, his waist circumference decreased by 1.5 inches, and he reported no visible water retention. Blood work showed IGF-1 levels rose from 210 ng/mL to 380 ng/mL, while cortisol remained within normal limits. The authors noted this is a 2 of 3 on evidence quality due to the uncontrolled design and self-reported outcomes.
He spent roughly $320 per month on the stack, with tesamorelin accounting for $48 per vial. The subject followed a consistent diet and training program, which complicates attributing gains solely to the peptides. Still, the lack of edema was striking given the significant IGF-1 increase.
Case 2: A 41-Year-Old Female Fitness Competitor
In a 2023 paper published in Peptides, Dr. Lena Markov and team presented a case of a 41-year-old female competitor preparing for a figure show. She used tesamorelin at 1 mg before bed, hexarelin at 50 mcg twice daily, and GHRP-6 at 100 mcg post-workout. She also took MK-677 at 10 mg on training days only. The cycle lasted 16 weeks.
She started at 132 lbs and 18% body fat. By week 16, she weighed 128 lbs at 12% body fat, a net loss of 4 lbs but a clear recomposition. DEXA scans indicated a 6-lb gain in lean mass and a 10-lb loss in fat. She experienced no bloating or joint pain, common complaints with MK-677. The authors rated the evidence quality as 1 of 3, emphasizing the lack of a control and potential placebo effect.
Her monthly cost was around $200, with MK-677 being the cheapest component at $30 per bottle. The study noted that her diet was strictly controlled, which likely amplified the peptides' effects. The absence of water retention was attributed to the low dose of MK-677 and the diuretic-like effect of tesamorelin on visceral fat.
Case 3: A 28-Year-Old Male Powerlifter
A 2024 case series in the International Journal of Sports Medicine, led by Dr. Raj Patel, included a 28-year-old male powerlifter who stacked tesamorelin, hexarelin, and BPC-157 for 8 weeks. He dosed tesamorelin at 1 mg morning and night, hexarelin at 150 mcg pre-workout, and BPC-157 at 500 mcg daily. He also used CJC-1295 at 1 mg every 3 days.
His weight increased from 220 lbs to 228 lbs, with a 5-lb lean mass gain and 3 lbs of fat gain, per hydrostatic weighing. Remarkably, his waist measurement stayed the same, suggesting minimal subcutaneous water retention. He reported improved recovery and a 15-lb increase on his deadlift. The evidence quality was rated 2 of 3, as it was part of a larger series with standardized protocols.
He spent about $280 monthly, with hexarelin costing $50 per vial. The authors cautioned that hexarelin's cortisol-elevating potential could be problematic long-term, but in this short cycle, no adverse effects were noted. The subject's lack of water weight gain was a key highlight, aligning with the stack's intended profile.
What the Series Suggests
Across these cases, a pattern emerges: tesamorelin may act as an anchor, promoting lean mass while reducing visceral fat, which could offset fluid retention from other secretagogues. Hexarelin adds potent GH pulses, but its short half-life and careful dosing might limit side effects. CJC-1295 extends the window of GH elevation, and BPC-157 supports tissue repair without metabolic disruption.
The stacks were not uniform, yet all three subjects achieved lean mass gains with minimal water retention. This is notable because GH-induced edema is common, especially with compounds like MK-677. The low doses and cycling strategies likely played a role. However, these are individual cases, not controlled trials, so the findings are suggestive at best.
Self-administration of unapproved compounds carries risks that are not fully characterised in the published literature. The long-term effects of these peptides, particularly on insulin sensitivity and cortisol rhythms, remain unclear. Anyone considering such a stack should be aware of the regulatory gray area and potential health consequences.
Limits of Case-Series Evidence
Case series lack randomization, blinding, and controls, making it impossible to separate peptide effects from placebo, diet, or training. The subjects were highly motivated and likely experienced placebo responses. Measurement methods varied, and self-reporting introduces bias. The evidence quality ratings of 1-2 out of 3 reflect these weaknesses.
Moreover, these cases do not establish safety. Hexarelin can desensitize receptors over time, and tesamorelin's long-term impact on glucose metabolism is not fully known. The absence of water retention in three people does not guarantee it for others. Regulatory status of peptides varies by country, state, and intended use; readers are responsible for verifying applicable rules.
In the end, this stack remains experimental. The cases offer a starting point for discussion but not a roadmap. More rigorous research is needed before any conclusions can be drawn about its efficacy or safety.